Bulevirtide for chronic hepatitis delta
Treatments studied
Part of Digestive system, Infections clinical trials.
This study tests a daily shot of Bulevirtide for people with long-term hepatitis delta and early-stage cirrhosis. It aims to see if the medicine is safe and works well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have chronic hepatitis delta (a type of hepatitis D that lasts a long time)
- You have cirrhosis (scarring of the liver) that is still working well (compensated)
- You are planning to start Bulevirtide 2 mg daily starting May 2023
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well the drug bulevirtide (BLV) works over a long period for people with hepatitis D (HDV) and liver scarring that is still under control (compensated cirrhosis). It may help you if you have been taking BLV alone and want to see how your liver and health have been doing.
This trial tests a drug called bulevirtide for people with chronic hepatitis B and D (HDV) co-infection. It looks at how the immune system and virus respond to treatment.
This study looks at how Bulevirtide, a treatment for hepatitis D, affects bile acids and gut bacteria. It may help patients with chronic HDV and stable liver disease who are already on HBV therapy.
This study tests a drug called bulevirtide for people with chronic hepatitis B and D co-infection. It aims to see if the drug is safe and effective, and to study biomarkers that may help predict how well it works.
This trial tests a new drug, brelovitug, against an existing one, bulevirtide, for people with chronic hepatitis delta. It aims to find a better treatment to lower the virus and protect the liver.
This trial tests if switching from bulevirtide to brelovitug can help people with chronic hepatitis D (CHD). It is for adults who have been on bulevirtide for at least 6 months and still have detectable virus.
Hear when a new Hepatitis D trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.